Cancer - Adanate, Inc.

Cancer

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05601219

A Phase 1, Open-Label, Multicenter Study of ADA-011 as Monotherapy and in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors

Drug

ADA-011

Condition

NSCLC melanoma squamous cell carcinoma of the head and neck